
-
Where Are They Now? SQZ Biotech5/1/2024
SQZ Biotech, a novel cell therapy company with Big Pharma backing, is no more. However, the company's science, and its founding CEO, will continue on under new auspices.
-
Reviva Pharma's Novel Funding Approach In Schizophrenia4/25/2024
Reviva Pharma CEO Laxminarayan Bhat, Ph.D. found a novel way to build an investor base for his company during a time when Big Pharma was exiting complicated CNS diseases. Now, Reviva has a late-stage schizophrenia candidate just as CNS is back in vogue.
-
Companies To Watch: OSE Immunotherapeutics4/22/2024
OSE Immunotherapeutics is poised to begin a confirmatory and pivotal Phase 3 trial for a novel cancer vaccine targeting the second line in NSCLC, an area of acute unmet need.
-
A View From The Co-Chair Of Israel's Biopharma Industry Trade Organization3/28/2024
Yaacov Michlin, co-chair of the IATI, discusses the advantages and disadvantages of Israel’s biopharma industry, the industry impact of the war in Gaza, and the difference between the U.S. and Israel regarding Chinese CDMOs.
-
Why Fusion Pharma Is The Latest Billion Dollar Big Pharma Buy In Radiopharmaceuticals3/22/2024
AstraZeneca's $2.4 billion acquisition of Fusion Pharma is the third billion dollar radiopharmaceuticals deal in recent months. John Valliant, Fusion's founder and CEO, explains why alpha-emitters are better than beta-emitters, and why radiopharmaceuticals are poised for substantial growth.
-
Where Are They Now? Novo Nordisk3/18/2024
In a few short years, Novo Nordisk has gone from belt-tightening to parachute pants, and is now replaying a GLP-1 competition with Eli Lilly that kicked off with Victoza and Trulicity ten years ago.
-
A Proactive Approach To 'Unscrupulous' Patent Practices3/7/2024
Terran Biosciences aims to subvert a patent strategy some drugmakers have used to delay the entrance of generic competitors. The company is patenting its own psychedelic salts, polymorphs, and prodrugs, and targeting FDA's 505(b)(2) pathway.
-
NORD Expands Advocacy And Support For Rare Disease Patients, And Industry2/29/2024
NORD's president and CEO, Peter Saltonstall, offers details on the organization's current activities and ongoing work with biopharmaceutical companies developing rare disease drugs.
-
The Good And Bad Of Copromotion2/26/2024
Are two minds, or companies, better than one for drug commercialization? It depends on the details, says Eisai's Paul Hawthorne.